BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20824907)

  • 1. Lenalidomide efficacy in bortezomib-resistant myeloma.
    Gozzetti A; Crupi R; Defina M; Bocchia M
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide for bortezomib-resistant multiple myeloma.
    Briani C; Berno T; Campagnolo M; Zambello R
    Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs: More shots on target.
    Appel A
    Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
    [No Abstract]   [Full Text] [Related]  

  • 4. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnosis and the current trends in multiple myeloma therapy.
    DmoszyƄska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical update: novel targets in multiple myeloma.
    Anderson KC
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
    Mellstedt H; Gimsing P; Waage A
    Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular-targeted therapy of multiple myeloma].
    Iida S
    Nihon Naika Gakkai Zasshi; 2010 Jan; 99(1):132-9. PubMed ID: 20376958
    [No Abstract]   [Full Text] [Related]  

  • 13. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents for multiple myeloma treatment.
    Ribatti D; Vacca A
    Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 18. Current therapy of myeloma induced renal failure.
    Gertz MA
    Leuk Lymphoma; 2008 May; 49(5):833-4. PubMed ID: 18452070
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current treatment strategies for multiple myeloma].
    Mey UJ
    Ther Umsch; 2010 Oct; 67(10):527-35. PubMed ID: 20886459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
    Takamatsu Y
    Rinsho Ketsueki; 2012 Jun; 53(6):587-93. PubMed ID: 22790633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.